Company: RKLIF
Filing Date: 2025-09-30
Form Type: 6-K
Source: 0001654954-25-011228
Chunk: 0

Company: RENTOKIL INITIAL PLC /FI
Filing Date: 2025-09-30
Form: 6-K
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549
#### ___________________

#### FORM 6-K
#### __________________

### REPORT OF FOREIGN PRIVATE ISSUER

#### PURSUANT TO RULE 13a-16 OR 15d-16

#### UNDER THE SECURITIES EXCHANGE ACT OF 1934
<div align='center'>For the month ofSeptember 2025</div>

#### Commission File Number: 001-41524
<div align='center'>___________________________________</div>

#### Rentokil Initial plc
<div align='center'>**(Registrant’s name)**</div>

#### ___________________________________

#### Compass House

#### Manor Royal

#### Crawley

#### West Sussex RH10 9PY

#### United Kingdom
<div align='center'>**(Address of principal executive office)**</div>

#### _____________________________________

<div align='center'>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐</div>

| Completion                                          
 of France Workwear business sale dated 30 September 
 2025                                                |

**30 September

Rentokil Initial completes sale of France Workwear business to H.I.G. Capital

Rentokil Initial plc (the "Company") is pleased to confirm the completion of the sale of its Workwear business in France to H.I.G. Capital, as first announced in May 2025. The sale values the business at an enterprise value of €410m (c.$480m), on a cash-free and debt-free basis, including an earn-out of up to €30m (c.$35m) based on the performance of the business in 2026.

Total net cash proceeds from the transaction are expected to total €370m (c.$435m), subject to final earn-out outcome. Proceeds will be allocated in-line with the balanced Rentokil Initial model, distributed towards deleveraging of the balance sheet, organic growth focused investment in the core business, and complementary bolt-on M&A activity.

The transaction is a continuation